SynthesisInternational journal of molecular sciences2025
The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions.
Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- GPCR-Driven Muscarinic M1 and Histamine H1 Receptor Signaling Converging on the PI3K/Akt/mTOR Pathway: Functional Integration in Neuroinflammation and Myelin Repair in Multiple Sclerosis.Molecular neurobiology · 2026Review
- Epstein-Barr Virus and Multiple Sclerosis: A Narrative Review on Prevention and the Concept of an Infection-Driven Disease.Biomedicines · 2026Review
- Animal models of multiple sclerosis: applications and future directions in disease research.Metabolic brain disease · 2026Review
- Elucidating the Causal Relationships Between B Cells, Dendritic Cells, and Multiple Sclerosis Pathogenesis.Brain and behavior · 2026Article
- Integrative analysis reveals the autoantibodyome neuroimmune signature of neurodegeneration.iScience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the pivotal role of B cells in the pathogenesis of multiple sclerosis (MS) is well established, their precise functions in disease mechanisms remain incompletely understood. For decades, MS-related B cell research has focused on identifying B cell antigens that could induce pathogenic antibodies contributing to the initiation and maintenance of CNS lesion formation and inflammation. In this review, we conducted a systematic literature search to compile and critically assess proposed antigens with respect to their specificity for MS and the plausibility of findings across different publications. We identified 26 antigens in total. Among these, 15 antigens did not demonstrate high specificity for MS, 9 antigens yielded controversial or contradictory results, and 2 antigens may still be regarded as provisional at the time of our analysis. Based on these findings, a primarily antibody-mediated mechanism driving initial lesion formation is not supported by current evidence, although it cannot be excluded entirely. Instead, a secondary immune response to CNS tissue damage-characterized by local antibody production and alternative B cell functions such as antigen presentation, cytokine secretion and cell-to-cell communication-appears more plausible. Taken together, our review highlights the necessity of expanding B cell-oriented MS research beyond antibody production to include a broader spectrum of B cell functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.